FindTrial
Sign In

To assess the Clinicopathological Features and Prevalence of patents with IgA Nephropathy from a Tertiary Care Hospital in Central India

PREVALENCE AND CLINICO PATHOLOGICAL PROFILE OF IgA NEPHROPATHY IN A TERITIARY CARE HOSPITAL IN CENTRAL INDIA - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/083747
Enrollment
100
Registered
2025-03-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N048- Nephrotic syndrome with other morphologic changes

Interventions

Control Intervention1: NIL: NIL

Sponsors

NONE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients of age more than 18 years diagnosed to have IgAN and on regular follow up. 2. All patients with IgAN on maintenance hemodialysis. 3. All newly diagnosed patients with IgAN. 4. All patients presenting to nephrology OPD with renal biopsy proven IgAN or willing for renal biopsy to be done in the department of nephrology in the past 4 yrs.

Exclusion criteria

Exclusion criteria: 1.All patients with age less than 18 yrs. 2. All patients with psychosocial illness or condition that may curtail their ability to consent or fulfill inclusion criteria no : 4. 3. All patients with systemic lupus erythematosis, henoch scholein purpura or liver disease.

Design outcomes

Primary

MeasureTime frame
To determine the prevalence of IgA nephropathy from a tertiary care hospital in central IndiaTimepoint: baseline—

Secondary

MeasureTime frame
1.To determine the varied symptoms/ syndromic presentation of IgAN . 2. To analyze the clinical profile of the patients based on biochemical parameters and determine the natural history of the patients in Indian population. 3. To determine the severity of IgAN based on renal biopsy at presentation. 4. To determine the demographic, age and gender variation in the presentation of the disease in central IndiaTimepoint: All parameters will be assessed at the baseline at the time of enrollment.—

Countries

India

Contacts

Public ContactManish Balwani

Datta Meghe Institute of Higher Education and Research

vijayjeyachandran2010@gmail.com9443363154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026